Acumen Pharmaceuticals, Inc. ABOS NASDAQ

Acumen Pharmaceuticals, Inc. (ABOS) generated $-19.1M in operating cash flow for quarter ending 2025-12-31. After capital expenditures of $0.00, free cash flow was $-19.1M.

Cash conversion ratio was 0.76x, suggesting some earnings are non-cash.

Criteria supported by this page:

• HEALTH (67/100, Partial) — cash generation is adequate but may not fully cover debt in stressed conditions
• MOAT (28/100, Fail) — limited free cash flow weakens the competitive position
• INCOME (?/100) — Cash conversion ratio was 0.76x suggests some earnings are non-cash items

Overall SharesGrow Score: 50/100 with 2/7 criteria passed.